Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19.

Authors :: Buryachkovskaya L
Lomakin N
Melkumyants A
Docenko J
Serebruany V
Source :: Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2021 Sep 24; Vol. 22 (3), pp. 549-551.
Publication Year :: 2021
Abstract: No abstract present.<br />Competing Interests: The authors declare no conflict of interest.<br /> (© 2021 The Author(s). Published by IMR Press.)

Subjects :: Anti-Inflammatory Agents adverse effects
Antibodies, Monoclonal, Humanized adverse effects
Blood Platelets ultrastructure
COVID-19 blood
COVID-19 diagnosis
Case-Control Studies
Erythrocytes ultrastructure
Humans
Leukocytes ultrastructure
Microscopy, Electron, Scanning
Prospective Studies
Treatment Outcome
Anti-Inflammatory Agents therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Blood Platelets drug effects
Erythrocytes drug effects
Leukocytes drug effects
COVID-19 Drug Treatment

Full Text Access

Tools